High Fever Occurring 4 to 5 Days Post-Transplant of Haploidentical Bone Marrow or Peripheral Blood Stem Cells after Reduced-Intensity Conditioning Associated with the Useof Post-Transplant Cyclophosphamide as Prophylaxis for Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 197-198

  O'Donnell, Paul ^a,b   Raj, Kavita ^c,d   Pagliuca, Antonio ^c,d,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MYELOABLATIVE AGENT;

ACUTE LEUKEMIA; ALLOGRAFT; BONE MARROW; BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOL; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LETTER; PERIPHERAL BLOOD STEM CELL; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; ADVERSE EFFECTS; ALLOTRANSPLANTATION; GRAFT VS HOST DISEASE; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; TREATMENT OUTCOME; UNRELATED DONORS;

BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEVER; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84927158878     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.008     Document Type: Letter

References (8)

1. Castagna L., Crocchiolo R., Furst S., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014, 20:724-729.
2. Raj K., Pagliuca A., Bradstock K., et al. Peripheral blood stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced intensity conditioning. Biol Blood Marrow Transplant 2014, 20:890-895.
3. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post transplantation cylophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
4. Raj K., Streetly M., Kazmi M., et al. Peripheral blood progenitor cell (PBPC) transplantation from haploidentical donors following reduced intensity conditioning (RIC) for high-risk hematolgic malignancies. Biol Blood Marrow Transplant 2012, 18S:331. abstr. 343.
5. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
6. Grosso D., Carabasi M., Filicko-O'Hara J., et al. Atwo-step approach to myeloablative haploidentical stem cell transplantation: a phase I/II trial performed with optimised T-cell dosing. Blood 2011, 118:4732-4739.
7. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
8. Kanakry C., O'Donnell P., Furlong T., et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JClin Oncol 2014, 32:3497-3505.